US › Healthcare

Veru Inc (VERU)

US · Healthcare · Biotechnology

$2.37+4.87%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$56,386
Net profit
$-2.7M
Profit YoY
+65.3%
EPS
$-0.13
EPS estimate
$-0.28
Net margin
-4,861.4%

EPS came in at -0.13 against a street estimate of -0.28 — a beat of 53.6%.

Key statistics

Market cap
$36.0M
Forward P/E
117.6
P/B
1.03
Book value
$2.17
EPS (TTM)
$-0.80
52-week high
$4.59
52-week low
$2.05
50-day MA
$2.68
200-day MA
$2.58
Beta
-1.20

Analyst view

Analysts rate Veru Inc a buy (4 buy, 1 hold, 0 sell out of 5) with an average price target of $24.50.

Shareholding

Insiders
9.78%
Institutions
24.58%

Largest institutional holders

FundStake
Alyeska Investment Group, L.P.6.23%
Vanguard Capital Management, LLC3.36%
Oppenheimer & Co Inc1.22%
GSA Capital Partners LLP1.18%
Geode Capital Management, LLC1.15%
Summit Financial LLC0.95%
Millennium Management LLC0.94%
Ikarian Capital, LLC0.83%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Veru Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.